Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Top Cited Papers
Open Access
- 18 March 2020
- journal article
- retracted article
- Published by Elsevier BV in Engineering
- Vol. 6 (10), 1192-1198
- https://doi.org/10.1016/j.eng.2020.03.007
Abstract
No abstract availableKeywords
Funding Information
- National Science and Technology Major Project (2017ZX10204401, 2018ZX10711001, 2017ZX10103011, 2018ZX09711003, 2020YFC0841700)
- Sanming Project of Medicine in Shenzhen (SZSM201412003, SZSM201512005)
- Shenzhen Science and Technology Research and Development Project (202002073000001)
- China Postdoctoral Science Foundation (2019M660836)
- Guangdong Special Fund for Science and Technology Innovation Strategy in 2020
- Department of Science and Technology of Guangdong Province (2020B111105001)
This publication has 16 references indexed in Scilit:
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- MERS-CoV: Understanding the Latest Human Coronavirus ThreatViruses, 2018
- Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in GuineaPLoS Medicine, 2016
- Ebola virus dynamics in mice treated with favipiravirAntiviral Research, 2015
- Favipiravir for children with EbolaThe Lancet, 2015
- Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal modelAntiviral Research, 2014
- Favipiravir (T-705), a novel viral RNA polymerase inhibitorAntiviral Research, 2013
- Computed tomography findings from patients with ARDS due to Influenza A (H1N1) virus-associated pneumoniaEuropean Journal of Radiology, 2012
- Pulmonary Sequelae in Convalescent Patients after Severe Acute Respiratory Syndrome: Evaluation with Thin-Section CTRadiology, 2005